Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which act independently of insulin, represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus (T2DM) management (Yaribeygi et al., 2020). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.